Comparison of costs for infusion versus bolus chemotherapy administration : Analysis of five standard chemotherapy regimens in three common tumors-part one : Model projections for cost based on charges.
The cost of infusional administration of cancer chemotherapy has been assumed to be more expensive than the traditional bolus schedule related to the use of durable medical equipment and other components of the delivery system.
The objective was to develop a model of projected charges as a basis for the cost estimate for selected common chemotherapy regimens comparing the cost based on charges for bolus and infusional chemotherapy schedules.
Chemotherapy programs using either bolus or infusional delivery were selected representing standard or commonplace regimens for the treatment of patients with breast cancer (cyclophosphamide, methotrexate, fluorouracil [CMF] or CA) ; colon cancer (5-fluorouracil[5-FU] infusion vs. 5-FU bolus+leucovorin [LCV]) or lymphoma (cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), prednisone ICHOP] or CDE [cyclophosphamide, doxorubicin, etoposide]). Cost projections were estimated based on charges and were calculated in a model system using six charge (cost) centers including medical doctor [MD] and/or clinic visit ; laboratory ; drug cost based on average wholesale price (AWP) ; cost of disposables ; and pump rental fee.
Standard dosages were applied for each regimen using total mg/M2 for a 1.5 M2 person.
Projected charges for chemotherapy for colon cancer (5-FU infusion vs. 5-FU+LCV) are variable depending on the LCV dose and the infusion duration. (...)
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Côlon, Lymphome non hodgkinien, Homme, Chimiothérapie, Traitement, Voie intraveineuse, Perfusion, Injection bolus, Analyse coût, Etude comparative, Anticancéreux, Glande mammaire pathologie, Appareil digestif pathologie, Intestin pathologie, Côlon pathologie, Hémopathie maligne, Lymphoprolifératif syndrome, Economie santé
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Colon, Non Hodgkin lymphoma, Human, Chemotherapy, Treatment, Intravenous administration, Perfusion, Bolus injection, Cost analysis, Comparative study, Antineoplastic agent, Mammary gland diseases, Digestive diseases, Intestinal disease, Colonic disease, Malignant hemopathy, Lymphoproliferative syndrome, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0329346
Code Inist : 002B02R02. Création : 10/04/1997.